Analyst consensus rating
ORIC Pharmaceuticals Analyst Rating: Strong Buy
ORIC is rated Strong Buy by 12 analysts with a $20.67 target. As of 2026-08-27.
Direct answer
ORIC Pharmaceuticals's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.67.
Forecast evidence checked August 27, 2026.
Get free ORIC Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $13.91
- Average price target
- $20.67
- High price target
- $27.00
- Low price target
- $14.00
- Low target gap
- +0.6%
- Target upside
- +48.6%
- High target gap
- +94.1%
- Target range width
- 93.5%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ORIC Pharmaceuticals?
ORIC Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $20.67.
How far are ORIC Pharmaceuticals's low and high targets from the recorded price?
The low target implies +0.6%, while the high target implies +94.1%.
How many analysts are included in ORIC Pharmaceuticals's consensus?
The verified consensus includes 12 analysts.
How is ORIC Pharmaceuticals's target upside or downside calculated?
The average target of $20.67 is divided by the recorded price of $13.91, then one is subtracted to produce +48.6%. This does not guarantee a future return.
When was ORIC Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.